431 related articles for article (PubMed ID: 9949205)
1. Methylation profiling of CpG islands in human breast cancer cells.
Huang TH; Perry MR; Laux DE
Hum Mol Genet; 1999 Mar; 8(3):459-70. PubMed ID: 9949205
[TBL] [Abstract][Full Text] [Related]
2. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
3. Predicting aberrant CpG island methylation.
Feltus FA; Lee EK; Costello JF; Plass C; Vertino PM
Proc Natl Acad Sci U S A; 2003 Oct; 100(21):12253-8. PubMed ID: 14519846
[TBL] [Abstract][Full Text] [Related]
4. A multifactorial signature of DNA sequence and polycomb binding predicts aberrant CpG island methylation.
McCabe MT; Lee EK; Vertino PM
Cancer Res; 2009 Jan; 69(1):282-91. PubMed ID: 19118013
[TBL] [Abstract][Full Text] [Related]
5. De novo methylation of CpG island sequences in human fibroblasts overexpressing DNA (cytosine-5-)-methyltransferase.
Vertino PM; Yen RW; Gao J; Baylin SB
Mol Cell Biol; 1996 Aug; 16(8):4555-65. PubMed ID: 8754856
[TBL] [Abstract][Full Text] [Related]
6. CpG island arrays: an application toward deciphering epigenetic signatures of breast cancer.
Yan PS; Perry MR; Laux DE; Asare AL; Caldwell CW; Huang TH
Clin Cancer Res; 2000 Apr; 6(4):1432-8. PubMed ID: 10778974
[TBL] [Abstract][Full Text] [Related]
7. DNA methylation and ovarian cancer. I. Analysis of CpG island hypermethylation in human ovarian cancer using differential methylation hybridization.
Ahluwalia A; Yan P; Hurteau JA; Bigsby RM; Jung SH; Huang TH; Nephew KP
Gynecol Oncol; 2001 Aug; 82(2):261-8. PubMed ID: 11531277
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide profiling of CpG methylation identifies novel targets of aberrant hypermethylation in myeloid leukemia.
Gebhard C; Schwarzfischer L; Pham TH; Schilling E; Klug M; Andreesen R; Rehli M
Cancer Res; 2006 Jun; 66(12):6118-28. PubMed ID: 16778185
[TBL] [Abstract][Full Text] [Related]
9. Dissecting complex epigenetic alterations in breast cancer using CpG island microarrays.
Yan PS; Chen CM; Shi H; Rahmatpanah F; Wei SH; Caldwell CW; Huang TH
Cancer Res; 2001 Dec; 61(23):8375-80. PubMed ID: 11731411
[TBL] [Abstract][Full Text] [Related]
10. Methylation of the p16(Ink4a) tumor suppressor gene 5'-CpG island in breast cancer.
Nielsen NH; Roos G; Emdin SO; Landberg G
Cancer Lett; 2001 Feb; 163(1):59-69. PubMed ID: 11163109
[TBL] [Abstract][Full Text] [Related]
11. Methylation target array for rapid analysis of CpG island hypermethylation in multiple tissue genomes.
Chen CM; Chen HL; Hsiau TH; Hsiau AH; Shi H; Brock GJ; Wei SH; Caldwell CW; Yan PS; Huang TH
Am J Pathol; 2003 Jul; 163(1):37-45. PubMed ID: 12819009
[TBL] [Abstract][Full Text] [Related]
12. DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines.
Roll JD; Rivenbark AG; Jones WD; Coleman WB
Mol Cancer; 2008 Jan; 7():15. PubMed ID: 18221536
[TBL] [Abstract][Full Text] [Related]
13. Hypermethylation leads to silencing of the SYK gene in human breast cancer.
Yuan Y; Mendez R; Sahin A; Dai JL
Cancer Res; 2001 Jul; 61(14):5558-61. PubMed ID: 11454707
[TBL] [Abstract][Full Text] [Related]
14. TMS1, a novel proapoptotic caspase recruitment domain protein, is a target of methylation-induced gene silencing in human breast cancers.
Conway KE; McConnell BB; Bowring CE; Donald CD; Warren ST; Vertino PM
Cancer Res; 2000 Nov; 60(22):6236-42. PubMed ID: 11103776
[TBL] [Abstract][Full Text] [Related]
15. Role of the cytosine DNA-methyltransferase and p16INK4a genes in the development of mouse lung tumors.
Belinsky SA
Exp Lung Res; 1998; 24(4):463-79. PubMed ID: 9659578
[TBL] [Abstract][Full Text] [Related]
16. Aberrant de novo methylation of the p16INK4A CpG island is initiated post gene silencing in association with chromatin remodelling and mimics nucleosome positioning.
Hinshelwood RA; Melki JR; Huschtscha LI; Paul C; Song JZ; Stirzaker C; Reddel RR; Clark SJ
Hum Mol Genet; 2009 Aug; 18(16):3098-109. PubMed ID: 19477956
[TBL] [Abstract][Full Text] [Related]
17. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing.
Gonzalez-Zulueta M; Bender CM; Yang AS; Nguyen T; Beart RW; Van Tornout JM; Jones PA
Cancer Res; 1995 Oct; 55(20):4531-5. PubMed ID: 7553622
[TBL] [Abstract][Full Text] [Related]
18. Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation.
Graff JR; Herman JG; Myöhänen S; Baylin SB; Vertino PM
J Biol Chem; 1997 Aug; 272(35):22322-9. PubMed ID: 9268383
[TBL] [Abstract][Full Text] [Related]
19. Mapping of ER gene CpG island methylation-specific polymerase chain reaction.
Lapidus RG; Nass SJ; Butash KA; Parl FF; Weitzman SA; Graff JG; Herman JG; Davidson NE
Cancer Res; 1998 Jun; 58(12):2515-9. PubMed ID: 9635570
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells.
Nguyen C; Liang G; Nguyen TT; Tsao-Wei D; Groshen S; Lübbert M; Zhou JH; Benedict WF; Jones PA
J Natl Cancer Inst; 2001 Oct; 93(19):1465-72. PubMed ID: 11584062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
